IP Library Granted Patent US 9,833,514
Granted Patent B2
US 9,833,514 · App. 15/155,770 · Granted Dec 5, 2017

Use of pegylated IL-10 to treat cancer

Inventors: Martin Oft (Palo Alto, CA); Catherine Sheppard (San Francisco, CA); John Brian Mumm (Los Altos Hills, CA); Lingling Wu (Palo Alto, CA)
Assignee: Merck Sharp & Dohme Corp.
A61K47/48215A61K38/2066A61K39/39558A61K45/06A61K47/60C07K16/30C07K16/3015C07K16/3023C07K16/3046C07K16/3069C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,833,514
App. No.
15/155,770
Granted
Dec 5, 2017
Kind
B2
Abstract

Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.

Claims (9)

1. A method of inhibiting or reducing growth of a tumor or cancer in a subject in need thereof, the method comprising:

administering to the subject an effective amount of a pegylated interleukin-10 (PEG-IL-10) in combination with a folic acid analog, 5-fluorouracil and a platinum analog.

2. The method of claim 1 , wherein the PEG-IL-10 comprises a methoxy-PEG-aldehyde (PALD-PEG) linker.

3. The method of claim 1 , wherein the tumor or cancer is selected from the group consisting of colon cancer, ovarian cancer, breast cancer, melanoma, lung cancer, glioblastoma, and lymphoma.

4. The method of claim 3 , wherein the subject is human.

5. The method of claim 4 , wherein the PEG-IL-10 is human PEG-IL-10 (PEG-hIL-10).

6. The method of claim 1 , wherein the tumor or cancer is selected from the group consisting of epithelial cell cancer, endothelial cell cancer, squamous cell carcinoma, papillomavirus-induced cancer, adenocarcinoma, carcinoma, melanoma, sarcoma, and teratocarcinoma.

7. The method of claim 6 , wherein the subject is human.

8. The method of claim 7 , wherein the PEG-IL-10 is human PEG-IL-10 (PEG-hIL-10).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2016
From: OFT, MARTIN; SHEPPARD, CATHERINE; MUMM, JOHN
To: SCHERING CORPORATION
Reel/Frame 040188/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2016
From: WU, LINGLING
To: SCHERING CORPORATION
Reel/Frame 040188/0643 →
CHANGE OF NAME Recorded Nov 1, 2016
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 040542/0270 →
Continuity (7)
Continuation 14485315 · Sep 12, 2014
Continuation 12976063 · Dec 22, 2010
Continuation 12463825 · May 11, 2009
Continuation 11862626 · Sep 27, 2007
Provisional Application 60915603 · May 2, 2007
Provisional Application 60848326 · Sep 28, 2006
Related Publication 20160367689A1 · Dec 22, 2016